BRAF and colorectal carcinoma: Neither KRAS exon 2, 3, 4 nor BRAF exon 15 mutations were significantly associated with outcome; although BRAF-mutant CRC was associated with a 75% increased risk of death, the low number of cases precluded it from becoming statistically significant.